Intermittent neuroleptic treatment of therapy-resistant schizophrenic psychoses

European Journal of Psychiatry

Volumn 11, Issue 2, 1997, Pages 69-71

  A Campo J ^a   Nijman, H ^a   Merckelbach, H ^b  

^a Psychiatric Hospital Welterhof   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Neuroleptic withdrawal; Neuroleptics; Schizophrenia; Therapy resistance

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; HUMAN; HUMAN TISSUE; LONG TERM EXPOSURE; NEUROLEPTIC INDUCED DEFICIT SYNDROME; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0030758764     PISSN: 02136163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. BRENNER, HD., DENCKER, SJ., GOLDSTEIN, MJ., HUBBARD, JW, KEEGAN, DL., KRUGGER, G., KULHANEK, F., LIBERMAN, RP., MALM, U & MIDHA, KK. Defining treatment refractoriness in schizophrenia. Shiz. Bull. 16, 551-562, 1990.
2. KAY, SR , OPLER, LA. & FISZBEIN, A. Positive and negative syndrome scale (PANSS) rating manual. Department of Psychiatry, Albert Einstein College of Medicine, Montefiore Medical Center, and Schizophrenia Research Unit, Bronx Psychiatric Center. 1986.
3. MELTZER, HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schiz. Bull. 18, 515-542. 1992.
4. GATTAZ, WF & KÖLLISCH, M. Bromocriptme in the treatment of neuroleptic-resistant schizophrenia. Biol. Psyhiatry 21: 519-521. 1986.
5. SIEGEL, S. Classical conditioning, drug tolerance, and drug dependence. In R. Smart (Ed.) Research advances in alcohol and drug problems. Vol. 7. New York, Plenum, 207-246. 1983.